Listen Score
LS 29
Global Rank
TOP 10%

MENGENAI PODCAST INI 🔗

Purata panjang audio:
14 minutes
Bahasa Inggeris
Amerika Syarikat
9 episod
sejak 15 Dis 2021
episodic

EPISOD TERKINI 🔗

New biosimilars are coming to market and there is a lot of confusion among patients about what this will mean for their treatment plan. We called on patient advocates Cristina Montoya and Lene Andersen to hear directly about their experience on a biologic and biosimilar, respectively. In this f ...

CARI EPISOD LEPAS

Cari episod lepas bagi Breaking Down Biosimilars.

EPISOD SEBELUMNYA

Through conversations with patient advocates Cristina Montoya and Lene Andersen, we learn that many of the emotions and discussions around starting (and staying on) a treatment are in fact the same for biosimilars and biologics. In the second of a two-part episode, Cristina and Lene discuss tha ...
Many patients have questions and may be reluctant to make the switch to biosimilars at first. In this episode, hosts Zoe Rothblatt and Conner Mertens talk to a few patients about their experiences starting a biosimilar. They discuss some of the hurdles they face, like overcoming hesitancy, getti ...
Biosimilar medications must still win approval by the U.S. Food and Drug Administration. In this episode, co-hosts Zoe Rothblatt and Conner Mertens explore that approval process, and explain the unique naming convention the FDA came up with for biosimilars. “They were really, really drive ...
In this episode, Zoe and Conner check in with several patients who’ve made the switch to a biosimilar to find out how they’re doing. Some patients taking a biosimilar have to travel to an infusion site to receive their medication, while others inject their medication at home. In thos ...
When biosimilars were introduced into the US, there was much talk about how much money they could potentially save patients. Getting a biosimilar developed and approved by the US Food & Drug Administration (FDA) is not as rigorous or time-consuming as for a biologic … which was touted ...
Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the prolifer ...
The introduction of biosimilars in the US has been hampered by unrealized cost savings, myths and misinformation, and patient hesitancy. Still, many medical professionals see much to be optimistic about in the next few years. New biosimilars will soon be approved for the US market, and expectati ...
Biosimilar medications were introduced into the US market in 2015, but they’re still relatively unfamiliar to many people. In our first episode, co-hosts Zoe Rothblatt and Conner Mertens provide an overview of biosimilars – what they are, how they can help with certain medical condit ...
Anda telah melihat semua episod podcast ini
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada Global Healthy Living Foundation, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.